The c-erbB-2 Protein in Primary and Metastatic Breast Carcinomas

References

• Yokota J, Toyoshima A, Sugimura T, et al. Amplification of c-erbB-2 oncogene in human adenocarcinoma in vivo. Lancet 1986; 1: 765–767
   PubMed Web of Science ®Google Scholar
• Venter F J, Kumar S, Tuzi N L, Gullick W J. Over-expression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification. Lancet 1987; 2: 69–72
   PubMed Web of Science ®Google Scholar
• Zhou D, Battifora H, Yokota J, Yamamoto T, Cline M J. Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer. Cancer Res. 1987; 47: 6123–6125
   PubMed Web of Science ®Google Scholar
• Berger M S, Locher G W, Saurer S, et al. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res. 1988; 48: 1238–1243
   PubMed Web of Science ®Google Scholar
• Slamon D J, Godolphin W, Jones L A, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707–712
   PubMed Web of Science ®Google Scholar
• Wright C, Angus B, Nicholson S, et al. Expression of c-erbB-2 oncoprotein. A prognostic indicator in human breast cancer. Cancer Res. 1989; 49: 2087–2090
   PubMed Web of Science ®Google Scholar
• Borresen A-L, Ottestad L, Gaustad A, et al. Amplification and protein over-expression of the neu/HER-2/c-erbB-2 protooncogene in human breast carcinomas: relationship to loss of gene sequences on chromosome 17, family history and prognosis. Br J Cancer. 1990; 62: 585–590
   PubMed Web of Science ®Google Scholar
• Slamon D J, Clark G M, Wong S G, Levin W J, Ullrich A, McGuire W L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177–182
   PubMed Web of Science ®Google Scholar
• Tsuda H, Hirohashi S, Shimosato Y, et al. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units; hst-1/int-2 and c-erbB-2/ear-1. Cancer Res. 1989; 49: 3104–3108
   PubMed Web of Science ®Google Scholar
• Walker R A, Gullick W J, Varley J M. An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer. Br J Cancer. 1989; 60: 426–429
   PubMed Web of Science ®Google Scholar
• De Potter C R, Beghin C, Makar A P, Vande-Kerckhove D, Roels H J. The neu-oncogene protein as a predictive factor for haematogenous metastases in breast cancer patients. Int J Cancer. 1990; 45: 55–58
   PubMed Web of Science ®Google Scholar
• Makar A P, Desmedt E J, De Potter C R, Van-Derheyden J S, Schatteman E A. Neu (c-erbB-2)oncogene in breast cancer and its possible association with the risk of distant metastases. Acta Oncol. 1990; 29: 1–4
   PubMedGoogle Scholar
• Tsuda H, Hirohashi S, Shimosato Y, et al. Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. Cancer 1990; 65: 1794–1800
   PubMedGoogle Scholar
• Ali I U, Campbell G, Lidereau R, Callahan R, Slamon D J, Clark G M. Amplification of c-erbB-2 and aggressive human breast tumors?. Science 1988; 240: 1795–1796
   PubMedGoogle Scholar
• Barnes D M, Lammie G A, Millis R R, Gullick W L, Allen D S, Altman D G. An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. Br J Cancer. 1988; 58: 448–452
   PubMed Web of Science ®Google Scholar
• Zhou D-J, Ahuja H, Cline M J. Proto-oncogene abnormalities in human breast cancer: c-erbB-2 amplification does not correlate with recur-rence of disease. Oncogene. 1989; 4: 105–108
   PubMed Web of Science ®Google Scholar
• De Potter C R, Van Daele S, Van de Vijver M J, et al. The expression of the neu oncogene product in breast lesions and in normal fetal and adult human tissues. Histopathology 1989; 15: 351–362
   PubMedGoogle Scholar
• Lammie G A, Barnes D M, Millis R R, Gullick W J. An immunohistochemical study of the presence of c-erbB-2 protein in Paget's disease of the nipple. Histopathology 1989; 15: 505–514
   PubMed Web of Science ®Google Scholar
• Ramachandra S, Machin L, Ashley S, Monaghan P, Gusterson B A. Immunohistochemical distribution of c-erbB-2 in in situ breast carcinoma-a detailed morphological analysis. J Pathol. 1990; 161: 7–14
   PubMed Web of Science ®Google Scholar
• Van der Vijver M J, Mooi W J, Wisman P, Pe-Terse J L, Nusse R. Immunohistochemical detection of the neu protein in tissue sections of human breast tumors with amplified neu DNA. Oncogene. 1988; 2: 175–178
   PubMed Web of Science ®Google Scholar
• Nesland J M, Ottestad L, Heikkilä R, Holm R, Tveit K, Borresen A-L. C-erbB-2 protein and neuroendocrine expression in breast carcinomas. Anticancer Res., in press
   Google Scholar
• Hsu S-M, Raine L, Fanger H. A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol. 1981; 75: 734–738
   PubMed Web of Science ®Google Scholar
• Ottestad L, Tveit K M, Nesland J M, et al. The immunocytochemical method for assaying oestrogen receptors in breast cancers. A comparison with the steroid binding assay. Histol Histopathol. 1988; 3: 269–274
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Ikawa S, Akiyama T, et al. Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor. Nature (London) 1986; 319: 230–234
   PubMed Web of Science ®Google Scholar
• Myers J C, Dickson L A, Dewet W J, et al. Analysis of the 3′ end of the human pro-α2(i) collagen gene. J Biol Chem. 1983; 258: 10128–10135
   PubMedGoogle Scholar
• Feinberg A P, Vogelstein V. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Bio-chem. 1983; 132: 6–13
   Google Scholar
• Gusterson B A, Machin L G, Gullick W J, et al. C-erbB-2 expression in benign and malignant breast disease. Br J Cancer. 1988; 58: 453–457
   PubMed Web of Science ®Google Scholar
• Heintz N H, Leslie K O, Rogers L A, Howard P L. Amplification of the c-erbB-2 oncogene and prognosis of breast adenocarcinoma. Arch Pathol Lab Med. 1990; 114: 160–163
   PubMed Web of Science ®Google Scholar
• Borg Å, Linell F, Idvall I, et al. HEH2/neu amplification and comedo type breast carcinoma. Lancet 1989; 1: 1268–1269
   PubMedGoogle Scholar
• Bacus S S, Bacus J W, Slamon D J, Press M F. HER-2/neu oncogene expression and DNA ploidy analysis in breast cancer. Arch Pathol Lab Med. 1990; 114: 164–169
   PubMedGoogle Scholar
• Nesland J M, Memoli V A, Holm R, Gould V E, Johannessen J V. Breast carcinomas with neuroendocrine differentiation. Ultrastruct Pathol. 1985; 8: 225–240
   PubMed Web of Science ®Google Scholar
• Nesland J M, Holm R, Johannessen J V. A study of different markers for neuroendocrine differentiation in breast carcinomas. Pathol Res Pract. 1986; 181: 524–530
   PubMed Web of Science ®Google Scholar
• Hudziak R M, Lewis G D, Winget M, Fendly B M, Shepard H M, Ullrich A. p18HER2 Monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol. 1989; 9: 1165–1172
   PubMed Web of Science ®Google Scholar
• Hung M-C, Yan D-H, Zhao X. Amplification of the proto-neu oncogene facilitates oncogenic activation by a single point mutation. Proc Natl Acad Sci USA 1989; 86: 2545–2548
   PubMed Web of Science ®Google Scholar
• Bouchard L, Lamarre L, Temblay P J, Jolicoeur P. Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 1989; 57: 931–936
   PubMed Web of Science ®Google Scholar